Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker
NCT ID: NCT03659643
Last Updated: 2018-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2018-01-01
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
NCT06826157
Evaluation of Cognitive State in Senior Subjects Using Neurosteer EEG System
NCT04683835
Exploring Feasibility, Acceptability and Impact of Using Neurofeedback with Persons with Mild Cognitive Impairment
NCT06762522
Evaluation of Cognitive State Using Neurosteer EEG System
NCT04386902
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
NCT00938665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the second part of the study (n=120), new patients evaluated in the Memory Clinics and diagnosed with MCI (not SCI) are invited to participate for a two year follow up.
In the diagnostic work-up, simple screening tests and information from a close relative form the basis of the cognitive status (SCI;MCI, Dementia). In evaluating the cause of cognitive impairment, detailed neuropsychological testing is performed as well as MRI of the brain and CSF for Alzheimer´s markers. qEEG with SPR analysis is registered but the clinician is blinded to its outcome.
The end point in both parts of the study is a diagnosis of a dementing disorder.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective MCI cohort
EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
EEG with SPR analysis
qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
Prospective MCI cohort
New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
EEG with SPR analysis
qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EEG with SPR analysis
qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Exclusion Criteria
* Medically or psychologically unstable
* Living outside the capital region
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ullevaal University Hospital
OTHER
Karolinska University Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Zealand University Hospital
OTHER
Haukeland University Hospital
OTHER
Kavli Research Foundation, Bergen Norway
UNKNOWN
Jon Snaedal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jon Snaedal
Professor in Geriatric Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Knut Engedal, PhD
Role: STUDY_DIRECTOR
Ullevaal University Hospital. Oslo, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Landspitali University Hospital
Reykjavik, , Iceland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NORD-MCI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.